A Big Year Is Expected in Life Sciences Patent Litigation

Chad Shear sat down with Metropolitan Corporate Counselto discussnon-practicing entities, Hatch Waxman, the Biologics Price Competition and Innovation Act, inter partes reviews and more.

The interview discussed:

  • The latest issues and trends affecting Hatch-Waxman litigation
  • Global patent litigation strategies for life sciences companies
  • Patent litigation involving biosimilar and biologic drugs
  • Using post-grant proceedings to complement your patent litigation strategies